Core Insights - The strategic cooperation agreement between Guangzhou Pharmaceutical Group and JD Health aims to leverage digital innovation to enhance supply chain collaboration, market operations, and user services, ultimately providing consumers with more efficient health products and services [1][2] Group 1: Partnership Objectives - The partnership focuses on product innovation, channel co-construction, and service integration to boost health consumption confidence and explore joint investment and resource integration for industry upgrades [1][2] - Both companies aim to create a multi-layered, integrated cooperation system to optimize resource allocation and value release [1] Group 2: Historical Context and Growth - Since the deep cooperation began in 2017, the partnership has maintained a high compound growth rate of over 20% in business operations over the past three years, laying a solid foundation for this strategic upgrade [2] - The companies plan to establish a normalized, multi-level collaborative mechanism to enhance decision-making and execution [2] Group 3: Future Collaboration Focus - Future efforts will concentrate on precise procurement, intelligent inventory management, and automated replenishment to build an agile and efficient supply chain [3] - JD Health's big data analytics will enable Guangzhou Pharmaceutical's products to reach consumers more effectively, while leveraging JD Health's extensive logistics network to optimize warehousing, transportation, and delivery [3] Group 4: Market and User Engagement - The partnership will utilize JD Health's vast user resources and data capabilities to gain insights into user needs, enhancing service precision and personalization [3] - New products from Guangzhou Pharmaceutical will be prioritized for launch on JD Health's platform, with joint efforts in precision marketing to facilitate market entry [3] Group 5: Social Responsibility and Industry Transformation - The collaboration will also focus on corporate social responsibility, exploring mechanisms for the recycling of expired medications through existing platforms [3] - This partnership represents a significant step towards the integration of products, services, and platforms in the pharmaceutical and health industry [3]

京东健康CEO曹冬表示，广药集团是京东健康最重要的战略伙伴之一，希望未来能够更好地将广药的优 质产品与京东健康的数字能力、服务场景紧密结合，挖掘新的增长机会，共同为更多用户提供优质的健 康服务。 据悉，自2017年开启深度合作以来，广药集团与京东健康始终秉持互信共赢的理念，合作成果丰硕，过 去三年双方合作业务更是保持了20%以上的高复合增长，为此次战略升级奠定了坚实基础。 就合作项目的落地，广药集团党委副书记、副董事长、总经理陈杰辉表示，接下来双方构建常态化全层 级协同机制，决策层引领、执行层推进、业务层联动；深化优势互补，聚焦大品种拓展等领域突破；拓 展创新边界，共探出海等新场景合作，力争今年合作业务大幅增长，明年向更高目标迈进。 本报讯(记者王镜茹)10月21日，广州医药集团有限公司(以下简称"广药集团")与京东健康在广州签署战 略合作协议。 根据合作协议，双方将以数智创新为核心引擎，整合产品、渠道、技术和服务资源，围绕供应链协同、 市场运营、用户服务等维度，构建多层次、一体化的合作体系，推动资源高效整合与价值释放，为消费 者提供更高效、便捷的健康产品与服务体验。 广药集团党委书记、董事长李小军表示，此次 ...

Core Viewpoint - The strategic cooperation agreement between Guangzhou Pharmaceutical Group and JD Health aims to leverage digital innovation to enhance resource integration and value release in the pharmaceutical and healthcare industry [1][2]. Group 1: Strategic Cooperation - The agreement focuses on integrating products, channels, technology, and service resources to build a multi-layered, integrated cooperation system [1]. - Both companies aim to deepen collaboration in product innovation, channel development, and service integration, while exploring joint investment and resource integration for industry upgrades [1][2]. Group 2: Business Growth and Collaboration - Since their deep cooperation began in 2017, the partnership has achieved over 20% compound annual growth rate in business collaboration over the past three years [1]. - Future efforts will include establishing a regular collaboration mechanism across all levels, focusing on major product expansion and exploring new cooperation scenarios such as international markets [2]. Group 3: Supply Chain and User Services - The partnership will enhance supply chain efficiency through precise procurement, smart inventory management, and automated replenishment, utilizing JD Health's extensive delivery network [2]. - Guangzhou Pharmaceutical Group will leverage JD Health's user data to improve service precision and personalization, with new products launching first on JD Health's platform [2]. Group 4: Corporate Social Responsibility - Both companies will collaborate on a drug recycling initiative, combining Guangzhou Pharmaceutical Group's existing program with JD Health's public welfare platform [2].

Core Insights - JD Health and China National Pharmaceutical Group have signed a strategic cooperation agreement to enhance the accessibility of quality medical resources and promote health technology [1][2] - The partnership aims to launch innovative pharmaceutical products, including the first domestically approved tolvaptan patch and a sodium loxoprofen gel patch, through JD Health's online channels [1][2] Group 1: Strategic Partnership - JD Health and China National Pharmaceutical Group will collaborate in disease knowledge dissemination and new product launches [1] - The partnership is expected to leverage JD Health's online platform to improve public access to healthcare services [1][2] Group 2: Product Launches - JD Health will exclusively distribute the 2mg tolvaptan patch online, which is designed to alleviate symptoms of bronchial asthma and other obstructive airway diseases [1] - Another product, sodium loxoprofen gel patch, is the first in China to complete phase III clinical trials and is aimed at treating inflammation and pain from osteoarthritis and muscle injuries [1] Group 3: Market Trends - JD Health is positioned as the leading online health consumption platform, with e-commerce channels projected to account for 12.9% of the pharmaceutical retail market by 2024 [2] - The company employs a comprehensive "B2C + O2O + offline store" model to integrate supply chain, logistics, and medical resources effectively [2] Group 4: Future Collaboration - The partnership will expand to cover various disease areas, including oncology, rheumatology, and cardiovascular health, utilizing JD Health's internet hospital resources [2] - Both companies aim to transform authoritative medical knowledge into accessible content for the public, enhancing health education and chronic disease management [2]